Pleiotropic effects of ticagrelor: Myth or reality?

Omar Aït Mokhtar; Mélanie Gaubert; Marc Laine; Laurent Bonello; Regis Guieu; Jennifer Cautela; Michaël Peyrol; Jeremie Barraud; Franck Thuny; Françoise Dignat-Georges; Florence Sabatier; Julien Fromonot; Pascal Rossi; Franck Paganelli

doi:10.1016/j.acvd.2016.04.001

Pleiotropic effects of ticagrelor: Myth or reality?

Arch Cardiovasc Dis. 2016 Aug-Sep;109(8-9):445-8. doi: 10.1016/j.acvd.2016.04.001. Epub 2016 Jun 21.

Affiliations

¹ Department of Cardiology, CHU Mustapha Pacha, Alger, Algeria.
² Aix Marseille University and Department of Cardiology, North Hospital, chemin des Bourrely, 13008 Marseille, France.
³ Aix Marseille University and Department of Cardiology, North Hospital, chemin des Bourrely, 13008 Marseille, France. Electronic address: franck.paganelli@ap-hm.fr.

PMID: 27342807
DOI: 10.1016/j.acvd.2016.04.001

No abstract available

Keywords: Acute coronary syndrome; Adenosine plasma; Adénosine plasmatique; Antiplatelet; Antogoniste des récepteurs P2Y(12); P2Y(12) adenosine diphosphate receptor blocker; Syndrome coronaire aigu; Traitement anti-agrégant plaquettaire.

Publication types

Review

MeSH terms

Acute Coronary Syndrome / drug therapy*
Adenosine / analogs & derivatives*
Adenosine / pharmacology
Humans
Purinergic P2Y Receptor Antagonists / pharmacology
Ticagrelor
Treatment Outcome

Substances

Purinergic P2Y Receptor Antagonists
Ticagrelor
Adenosine